Retroviral agents containing anthranilamide, substituted benzami

Details Retroviral agents containing anthranilamide, substituted benzami Retroviral agents containing anthranilamide, substituted benzami

1995-11-22

1998-06-09

Davis, Zinna Northington

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

546335, C07D21370, A61K 3144

Patent

active

057634645

ABSTRACT:
The present invention provides novel retroviral agents containing anthranilamide, substituted benzamide, amino acid, and other subunits, a pharmaceutical composition comprising such compound, and a method of using such compounds to treat retroviral infections in mammals, specifically HIV and more specifically HIV-1 and HIV-2, in humans.

REFERENCES:
patent: 3838145 (1974-09-01), Ruedi Altermatt
patent: 4051196 (1977-09-01), Wells et al.
patent: 4568666 (1986-02-01), McCullagh et al.
patent: 5142056 (1992-08-01), Kempe et al.
patent: 5180744 (1993-01-01), Hanson et al.
patent: 5214129 (1993-05-01), Luly et al.
patent: 5254724 (1993-10-01), Bergeron, Jr.
patent: 5256677 (1993-10-01), Sham et al.
patent: 5272175 (1993-12-01), Hansen, Jr. et al.
patent: 5354866 (1994-10-01), Kempf et al.
Chemical Abstracts, vol. 124:145557, 1995 Randad et al.
Bone et al., "X-ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2-Symmetry," Journal of the American Chemical Society, 113(24), 9382-9384 (1991).
Randad et al., "Symmetry based HIV Protease Inhibitors: Rational Design of 2-Methylbenzamides as Novel P2/P2 Ligands," Bioorganic and Medical Chemistry Letters, 5(15), 1707-1712 (1995).
Erickson et al., "Design, Activity, and 2.8 .ANG. Crystal Structure of a C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249:527-533 (Aug. 1990).
Flentge et al., "Symmetry-Based Inhibitors of HIV Protease With High Oral Bioavailability," Abstract, Amer. Chem. Society Mtg. (1994).
Green et al., "Symmetry-Based HIV Protease Inhibitors: Structure-Based Design of P2 Amino Acid Replacements," Abstract, Amer. Chem. Society Mtg. (1993).
Kempf et al., "Antiviral and Pharmacokinetic Properties of C.sub.2 Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease," Antimicrobial Agents and Chemotherapy, 35(11):2209-2214 (Nov. 1991).
Kempf et al., "Design of Orally Bioavailable, Symmetry-Based Inhibitors of HIV Protease," Bioorganic & Medicinal Chemistry, 2(9):847-858 (1994).
Kempf et al., "Structure-Based, C.sub.2 Symmetric Inhibitors of HIV Protease," Journal of Medicinal Chemistry, 33(10):2687-2689 (1990).
Kempf et al, "Structure-Based Inhibitors of HIV Protease," Recent Advances in the Chem. of Anti-Infective Agents, Bently et al., eds. Royal Society of Chem., Cambridge (1993) pp. 297-313.
Kempf et al., "Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol," J. Med. Chem, 36:320-330 (1993).
Randad et al., "Symmetry-Based HIV Protease Inhibitors: Rational Design of Hydroxybenzamide as a Novel P.sub.2 Replacement," Abstract, AIDS Structure Mtg., NIH (1994).
Chemical Abstracts, vol. 116, No. 21, Abstract 214.912m, May 25, 1992, p. 792.
Chemical Abstracts, vol. 115, No. 5, Abstract 50301r, Aug. 5, 1991, p. 914.

Affiliated with

Also associated with

Rating

Retroviral agents containing anthranilamide, substituted benzami does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Retroviral agents containing anthranilamide, substituted benzami, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Retroviral agents containing anthranilamide, substituted benzami will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2199539